|
|
 |
 |
 |
| Scientific Program |
| |
** Please click on the hyperlinks below to view abstracts and Powerpoint presentations **
| 08:30-10:00 |
Hypoglycemia |
|
Capsule: Tradeoffs in achieving normoglycemia |
|
Chairperson: F. Kaufman, USA, N. Katsilambros, Greece |
|
08:30-09:00
|
G. Bolli, Italy |
|
09:00-10:00
|
Long acting analogues/pumps – the answer to the barrier
|
| |
|
| 10:30-12:30 |
Treatment of Type 2 Diabetes Mellitus (T2DM) |
|
Capsule: Should we aim at beta-cell-preserving treatments? Is there potential for beta-cell restoration? |
|
Chairpersons: S. Del Parto, Italy, N. Katsilambros, Greece |
|
10:30-11:30
|
Should PPARS be first-line therapy?
Pros: S. Del Prato, Italy
Cons: I. Raz, Israel |
|
11:30-12:30
|
Insulin as first-line therapy?
Pros: M. Massi Benedetti, Italy
Cons: E. Standl, Germany |
| |
|
|
13:30-15:30
|
Role of Glucose Levels in Diabetes
Capsule: Glycemic targets in clinical practice |
|
Chairperson: L. Leiter, Canada |
|
13:30-14:00
|
Pathophysiology of CV complications in diabetes
A. Ceriello, Italy |
|
14:00-14:30
|
Acute hyperglycemia as a prognostic marker in cerebrovascular disease
J. Tuomilehto, Finland |
|
14:30-15:00
|
Glycemic targets in clinical practice: What should be the focus?
Fasting preprandial glucose?
J. Gerich, USA |
|
15:00-15:30
|
Glycemic targets in clinical practice: What should be the focus?
Postprandial glucose?
J. Davidson, USA
|
|
16:00-18:00
|
Post-Prandial Glucose under Crossfire
Capsule: RTD: The value of measuring and treating post-prandial glucose |
|
Chairpersons: J. Gerich, USA, M. Hanefeld, Germany |
|
16:00-16:20
|
Glycemic variability- should we and can we prevent it?
L. Monnier, France |
|
16:20-16:40
|
The value of measuring and treating post-prandial hyperglycaemia – Evidence from prospective studies
|
|
16:40-17:00
|
Aiming at normal glycemia in hospitalized patients – is it feasible?
Can it improve outcome?
M. Marre, France |
|
17:00-17:30
|
Panel Discussion
A. Ceriello, Italy, M. Hanefeld, Germany, J. Gerich, USA,
L. Monnier, France |
| |
|
| 17:30-19:00 |
Free Communication |
|
Chairpersons: B. Hirshberg, USA, T. Herskovits, Israel |
|
17:30-17:45
|
3-month interim results on safety and efficacy of an oral insulin type-1 DM
J. Guevara-Aguirre, Ecuador |
|
17:45-18:00
|
CGMS™ in combination with KADIS® has a high potential to improve out-patient diabetes care
E. Salzsieder, Germany |
|
18:00-18:15
|
Carotid intima-media thickness in Type 1 diabetes children and adolescent
S. Chiaravalli, Italy |
|
18:15-18:30
|
Long-term survival of patients with diabetes mellitus and acute stroke
T. Pappa, Greece |
|
18:30-18:45
|
Triacylglycerol lipase activity in human adipose tissue during resistance exercise
A. Petridou, Greece |
|
18:45-19:00
|
Controversies regarding the screening of the metabolic syndrome
N. Hancu, Romania |
| Hall A - Diabetes |
| Saturday, October 28, 2006 |
| 08:00-09:30 |
Alternatives for Injected Insulin |
|
Capsule: Should we be satisfied with injected insulin or should we opt for more? |
|
Chairpersons: A. Pfeiffer, Germany, J. Roth, USA |
|
08:00-09:00
|
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes?
Pros: P. Home, UKCons: S. Efendic, Sweden Click here for Presentation |
|
09:00-09:30
|
Insulin resistance: Parsing pieces of the puzzle
J. Roth, USA |
| |
|
|
10:00-12:00 |
Novel Treatments to Cure Type 2 Diabetes Mellitus (T2DM) |
|
|
Capsule: Should we change treatment goals and strategy? |
|
Chairpersons: F. de Alvaro, Spain, P. Stein, USA |
|
10:00-10:30
|
Incertin and treatment of Type 2 diabetes
B. Gallwitz, Germany |
|
10:30-11:00
|
|
|
11:00-11:30
|
Treatment with injectable GLP-1 analogues: Advantages and disadvantages. Injectable GLP-1 vs. DPP-IV – is one more preferable then the other?
M. Nauck, Germany |
|
11:30-12:00
|
DPP-4 inhibitors: Is there a unique role for this new mechanism in the treatment of T2D?
P. Stein, USA |
|
12:00-14:00 |
Lunch Session |
|
A global call to action: targeting the continuum of cardiovascular risk |
|
12:30-12:40
|
Introduction
P. Home, UK |
|
12:40-13:00
|
confronting diabetes: The coronary heart disease (CHD) risk equivalent
|
|
13:00-13:20
|
Multiple comorbidities: Additive and predictive of CV risk
P. M. Nilsson, Sweden |
|
13:20-13:40
|
Achieving comprehensive CV risk reduction through integrated management of diabetes, obesity, hypertension and lipid disorders
A. Ceriello, Italy |
|
13:40-14:00
|
Questions & answers
Panel discussion |
| |
|
|
14:00-16:00 |
Normoglycemia and Cardiovascular Outcome |
| |
|
| 16:00-16:30 |
Coffee Break |
| |
|
| 16:30-17:30 |
Metabolic Syndrome / LADA |
|
|
Capsule: Are new and novel treatments more advantageous than the old ones? |
|
|
Chairpersons: P. Pozzilli, Italy, T. H. Jones, UK |
|
16:30-17:00
|
The Role of Testosterone in the Metabolic Syndrome
T. H. Jones, UK |
|
17:00-17:30
|
Metabolic syndrome and LADA: What type of therapeutic approach?
P. Pozzilli, Italy |
|
|
|
|
17:30-19:00 |
Free Communication |
|
Chairpersons: R. Calle, USA, Y. Yerushalmi, Israel |
|
17:30-17:45
|
Diagnosing diabetes and its subtypes with IVGTT
A. V. Dreval, Russia |
|
17:45-18:00
|
Undiagnosed diabetes mellitus in elderly subjects
R. S. Dankner, Israel |
|
18:00-18:15
|
Aortic distensibility in middle-aged subjects with diabetes
N. Tentolouris, Greece |
|
18:15-18:30
|
Definition of the Metabolic Syndrome increases the number of affected persons – analysis of 35 869 German primary care patients
S. Moebus, Germany |
|
18:30-18:45
|
Oral anticoagulation in diabetes and atrial fibrillation
O. Schnell, Germany |
|
|
|
| Hall A - Diabetes |
| Sunday, October 29, 2006 |
| 08:00-09:30 |
Continuous Glucose Monitoring (GCM) |
|
Capsule: Continuous glucose monitoring –how far are we from normoglycation? |
|
Chairpersons: M. Phillip, Israel, G. Soltesz, Hungary |
|
08:00-08:30
|
Do we need alternatives for insulin administration? Can long-acting analogues replace pump therapy?
|
|
08:30-09:00
|
Non-invasive glucose monitoring: Will the search for the “dream beam” ever come to an end?
L. Heinemann, Germany |
|
09:00-09:30
|
Accuracy of the FreeStyle Navigator continuous glucose monitoring system
K. Rebrin, USA |
|
11:30-13:30 |
Different Forms of Insulin |
|
Capsule: When is insulin preferable and in which form? |
|
Chairpersons: M. Riddle, USA, J. Wainstein, Israel |
|
11:30-12:30
|
Debate: Combined therapy - is there any advantage?
Pros: M. Riddle, USA Click here for Presentation
Cons: M. Massi Benedetti, Italy |
|
12:30-13:30
|
Debate: Insulin analogues versus pump therapy in Type 2 diabetes?
Insulin analogues: J. Davidson, USA
Pump therapy: E. M. Renard, France Click here for Presentation |
|
|
|
| Hall B - Diabetes, Hypertension and Related Complications |
| Friday, October 27, 2006 |
| 08:30-10:00 |
Target Blood Pressure |
|
Capsule: Is target blood pressure similar in young and elderly diabetic patients? |
|
Chairpersons: F. H. Messerli, USA, E. Grossman, Israel |
|
08:30-09:00
|
Should we lower systolic blood pressure below 160 mmHg in the very elderly diabetic patient?
C. Bulpitt, UK |
|
09:00-09:30
|
Can agressive lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
F. H. Messerli, USA |
|
09:30-10:00
|
Aggressive lowering of blood pressure in diabetes: the diastolic cost
|
|
10:30-12:30
|
Diabetic Neuropathy
Capsule: Diabetic neuropathy is one of the most difficult complications to control |
|
Chairpersons: R. Samigullin, Germany, D. Ziegler, Germany |
|
10:30-11:00
|
New targets for the treatment of diabetic neuropathy
A. Bierhaus, Germany |
|
11:00-11:30
|
Treatment of diabetic neuropathy / painful diabetic neuropathy- how far have we come?
D. Ziegler, Germany |
|
11:30-12:00
|
A. Boulton, UK |
|
12:00-12:30
|
Anemia in diabetic renal failure - is there a role for early erythropoietin treatment to prevent cardiovascular mortality?
G. Gambaro, Italy |
|
13:30-15:30
|
Role of Hyperglycemia in Cardiovascular Outcomes
Capsule: Post-prandial glucose spikes - are they important? |
|
Chairpersons: R. Bergenstal, USA, W. Scherbaum, Germany |
|
13:30-14:00
|
The independent risk factor of post-prandial hyperglycemia:
have enough evidence?
P. Pozzilli, Italy |
|
14:00-14:30
|
|
|
14:30-15:00
|
How far are we with regard to changing monitoring guidelines?
R. Bergenstal, USA |
|
15:00-15:30
|
Can different therapeutic regimens affect PPG spikes differently? Which is more effective - prandial insulin or oral hypoglycemics?
E. Standl, Germany |
| |
|
| 15:30-16:00 |
Coffee Break |
| |
|
|
16:00-18:00
|
Metabolic Syndrome
Capsule: Treatment to prevent or cure the metabolic syndrome beyond lifestyle |
|
Chairpersons: A. Tataranni, France, H. Ilkova, Turkey |
|
16:00-16:30
|
The role of the endocannabinoid system in cardiac risk factors
U. Pagotto, Italy |
|
16:30-17:00
|
Cardioprotection in the metabolic syndrome – how can we target mesenteric fat?
A.Tataranni, France |
|
17:00-17:30
|
Treatment beyond lifestyle for the metabolic syndrome: Prefer existing therapy (Metformin, PPAR gama/alpha, Orlistat)
|
|
17:30-18:00
|
Prefer novel therapy (Rimonabant, GLP/Antagonist)
I. Raz, Israel |
| |
|
| 18:00-19:00 |
Free Communication |
|
Chairperson: E. Berry, Israel, F. Adawi, Israel |
|
18:00-18:15
|
Reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley’s indices in patients with hypertension and Type 2 diabetes
P. A. Sarafidis, Greece |
|
18:15-18:30
|
The impact of high fructose diet and PPAR-γ agonist on Adiponectin levels and metabolic indices
Y. Sharabi, Israel |
|
18:30-18:45
|
Long-term survival in obese and non-obese patients after acute stroke
S. Skalidi , Greece |
|
18:45-19:00
|
Approaching cardio-metabolic risk: A quality improvement initiative
B. A. Al-Mustafa, Saudi Arabia |
|
|
|
Hall B - Diabetes, Hypertension and Related Complications |
| Saturday, October 28, 2006 |
| |
|
10:00-12:00 |
Nephropathy in Diabetes |
|
Capsule:Can progression and development of nephropathy be prevented? |
|
Chairpersons: D. De Zeeuw, Netherlands, A. Mimran, France |
|
10:00-10:30
|
Microalbuminuria in Type 2 diabetes - an underrated risk factor? can
we prevent it?
H. Haller, Germany |
|
10:30-11:00
|
Future treatment of albuminuria in diabetes and hypertension
D. De Zeeuw, Netherlands |
|
11:00-12:00
|
Is microalbuminuria the marker for nephropathy in diabetes, hypertension and general population?
Pros: D. De Zeeuw, Netherlands
Cons: A. Mimran, France |
| |
|
| 12:00-14:00 |
Lunch Session |
| |
|
|
|
| 17:30-18:30 |
Excessive Hypertension |
|
|
Capsule: The challenge remains - how should we treat the extreme cases of hypertension? |
|
Chairpersons: N. Weksler, Israel , Y. Yodfat, Israel |
|
17:30-18:30
|
|
| Hall B - Diabetes, Hypertension and Related Complications |
| Sunday, October 29, 2006 |
|
10:00-12:00
|
Diabetes and Cardiovascular Disease
Capsule: Should we be more aggressive in therapy? |
|
Chairpersons: J. Skrha, Czech Republic, A. Ametov, Russia |
|
10:00-10:30
|
Should we lower low-density lipoprotein (LDL) cholesterol to newborn levels? Is LDL more important than high-density lipoprotein (HDL)?
E. Steinhagen-Thiessen, Germany |
|
10:30-11:30
|
Should we prescribe statin and aspirin for every diabetic patient? Is it time for "polypill"?
Pros: A. K. Gitt, Germany
Cons: D. Tschope, Germany |
|
11:30-12:00
|
Diabetes, obesity and coronary disease, beyond glucose
G. Steiner, Canada |
| Hall C - Diabetes, Obesity and Related Complications |
| Friday, October 27, 2006 |
|
08:30-10:00
|
Obesity
Capsule: What is obesity? Is obesity of importance? |
|
Chairperson: P. Home, Uk |
|
Panel Discussion
E. M. Berry, Israel, V. Hainer, Czech Republic, H. Toplak, Austria,
C. Tsigos, Greece |
|
What is obesity? |
|
How does calorie intake/expenditure translate into mass? |
|
Is obesity of importance? Is it calorie load that is important? |
|
What are the dynamics of weight gain/loss? |
|
|
What are the dynamics of fat redistribution between metabolically different active tissues? |
|
What are the economics of obesity? |
| |
|
| 10:00-10:30 |
Coffee Break |
| |
|
|
10:30-12:30
|
Weight Loss
Capsule: Obesity is the epidemic of the century. Can we agree on what is the best way to achieve weight loss? |
|
Chairpersons: H. Toplak, Austria, S. Raptis, Greece |
|
10:30-11:30
|
Behavior and lifestyle versus pharmacotherapy
Behavior: A. Mitrakou, Greece
Pharmacotherapy: H. Toplak, Austria |
|
11:30-12:30
|
Surgical treatment of obesity – when and how?
The internist’s perspective: G. Schernthaner, Austria
The surgeon’s perspective: J. M. Morton, USA
|
|
|
|
|
12:30-13:30 |
Lunch |
| |
|
|
13:30-14:30
|
Weight Gain
Capsule: Pathogenesis of obesity and weight gain |
|
Chairpersons: V. Hainer, Czech Republic, G. Roman, Romania |
|
|
Drug-induced weight gain in depression – can it be avoided?
The internist's perspective: H. Toplak, Austria
The psychiatrist's perspective: E. Gur, Israel |
| |
|
| 14:30-15:30 |
Weight Loss in Type 2 Diabetes |
|
Capsule: Obesity complicates diabetes control |
|
Chairpersons: N. Hancu, Romania, S. Raptis, Greece |
|
14:30-15:00
|
Can we control blood glucose by special diets and weight reduction? Should we avoid refined sugars and include trace metals?
S. Rockwell, USA |
|
15:00-15:30
|
Were we wrong about the treatment of type 2 Diabetes?
S. Raptis, Greece |
| |
|
| 15:30-16:00 |
Coffee Break |
| |
|
|
16:00-17:30
|
Diabetes, Complications and Life Expectancy
Capsule: The importance of early effective treatment of diabetes and its complications is not debatable, but can this offset the decreased life expectancy? |
|
Chairpersons: W. Kerner, Germany, D. Tschope, Germany |
|
Panel Discussion
M. Petkova, Bulgaria, D. Dicker, Israel, E. Grossman, Israel, W. Kerner, Germany, D. Tschope, Germany |
|
The effect of the metabolic syndrome and diabetes on life expectancy |
|
|
Can tight control of glucose levels prolong life expectancy? |
|
|
How does obesity and hypertension affect life expectancy? |
|
|
The effect of secondary complications on life expectancy |
|
|
The effect of acute stress on life expectancy |
| |
|
| 17:30-19:00 |
Free Communication |
|
Chairpersons: Y. Yagil, Israel, G. Roman, Romania |
|
17:30-17:45
|
Abdominal obesity prevalence and waist circumference cutoffs for identifying hypertension and diabetes among healthy Israeli population
D. Dicker, Israel |
|
17:45-18:00
|
Step-by-step endoscopic treatment of obesity
E. Machytka, Czech Republic |
|
18:00-18:15
|
Multidimensional treatment for severe obesity: A cost analysis
G. M. Rovera, Italy |
|
18:15-18:30
|
Adaptive entero-omentectomy: physiological and evolutionary basis of an auxiliary treatment to type 2 diabetes. A surgical protocol ongoing in brazil
S. Santoro, Brazil |
|
18:30-18:45
|
Association of obesity with risk of developing breast cancer
C. Albala, Chile |
|
18:30-19:00
|
Evaluation of genetic predisposition to insulin resistance by nutrient- induced insulin output ratio (NIOR)
A.M. Dembinska-Kiec, Poland |
| Hall C - Diabetes, Obesity and Related Complications |
| Saturday, October 28, 2006 |
| |
| 08:00-09:30 |
Effect of Obesity and Diabetes on Internal Target Organs |
|
Capsule: Is fat accumulation the primary cause for target organ failure? |
|
Chairpersons: C. Tsigos, Greece, I. Raz, Israel |
|
08:00-08:30
|
Cardiovascular aspects of obesity
H. Gohlke, Germany |
|
08:30-09:00
|
Islet inflammation: Its relation to fat accumulation
M. Donath, Switzerland |
|
09:00-09:30
|
Abdominal fat and sleep apnea
G. Pillar, Israel Click here for Presentation |
| |
|
| 09:30-10:00 |
Coffee Break |
| |
|
|
10:00-12:00
|
Controlling Obesity
Capsule: What causes obesity? Is it the brain or periphery? Is it the gut or the fat? |
|
Chairperson: C. M. Rondinone, USA |
|
10:00-10:30
|
The mechanism of action of gastric bypass surgery and the role of the small bowel in the pathophysiology of obesity and type 2 diabetes
F. Rubino |
|
10:30-11:00 |
Can fat-secreted factors modulate human obesity and insulin resistance?
U. Smith, Sweden |
|
|
Glucocorticoid generation in the adernals and adipose tissue in obesity
B. R. Walker, UK Click here for Presentation |
|
11:30-12:00
|
Can gut hormones control appetite and prevent obesity?
S. Bloom, UK |
| |
|
| 12:00-14:00 |
Lunch Session |
| |
|
| 14:00-16:00 |
The Deleterious Effect of Obesity-Related Diabetes |
|
Capsule: Is obesity always bad? Mesenteric versus peripheral obesity |
|
Chairpersons: P. Nilsson, Sweden, G. Roman, Romania |
|
14:00-14:30
|
C. Tsigos, Greece |
|
14:30-15:00
|
The role of intrauterine and early life stress in obesity and metabolic syndrome
D. I. Phillips, UK |
|
15:00-15:30
|
Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?
P. Nilsson, Sweden |
|
15:30-16:00
|
Is there a solution resolving the controversy?
T. I. A. Sorensen, Denmark |
| |
|
| 16:00-16:30 |
Coffee Break |
| |
|
| 16:30-18:30 |
Childhood and Adolescent Obesity and Diabetes |
|
Capsule: Childhood and adolescent obesity - can we prevent it? Is it curable? |
|
Chairpersons: D. Pettitt, USA, G. Soltesz, Hungary |
|
16:30-17:00
|
Altered glucose metabolism in severely obesed children
R. Weiss, Israel |
|
17:00-18:00
|
The metabolically healthy obese: Should they be treated? Is there a way to identify diabetes - prone individuals? PCOS patients - is this a special subset of patients?
Pros: D. Pettitt, USA Click here for Presentation
Cons: F. Kaufman, USA |
|
|
Is education for proper lifestyle the answer?
F. Kaufman, USA |
| |
|
| 18:30-19:00 |
Free Communication |
|
Chairperson: R. Lichiardopol, Romania |
|
18:30-18:45
|
Increased Oxidative stress following a heat-processed meal in obese people with Type 2 diabetes Mellitus (T2DM): Cause for acute endothelial and adypocyte dysfunction?
A. O. Stirban, Germany |
|
18:45-19:00
|
Obesity causes heart rate changes in men, not in women
J. Rapoport, Israel |
|
|
| Hall C - Diabetes, Obesity and Related Complications |
| Sunday, October 29, 2006 |
| |
| 08:00-09:30 |
Obesity and Pregnancy Outcome |
|
Capsule: Obesity can complicate fertility and pregnancy outcome |
|
Chairperson: A. de-Leiva, Spain, Z. Ben Rafael, Israel |
|
08:00-08:30
|
Reproductive outcome in women with body weight disturbanses
|
|
08:30-09:00
|
Obesity versus huperglycemia: GDM outcome
A. de-Leiva, Spain |
|
09:00-09:30 |
Discussion |
| |
|
| 09:30-10:00 |
Coffee Break |
| |
|
|
10:00-11:30
|
Diabetes and Lipids
Capsule: Can we cure diabetes through lipid intervention? |
|
|
Chairpersons: M. Roden, Austria, G. Tomkin, Ireland |
|
10:00-10:30
|
The role of fat storage in the pathogenesis of metabolic disorder
M. Roden, Austria |
|
10:30-11:00
|
the target for intervention in dyslipidemia
G. Tomkin, Ireland |
|
11:00-11:30
|
Panel Discussion
M. Roden, Austria, E. Shafrir, Israel, G. Tomkin, Ireland |
| |
|
|
|
|
